
Bio-Techne (TECH) Stock Forecast & Price Target
Bio-Techne (TECH) Analyst Ratings
Bulls say
Bio-Techne is a global life science tools company with a strong focus on sustainability and a track record of successful self-help initiatives and transformative acquisitions. They have a solid growth outlook but face challenges in market conditions and product mix. Recent financials show improved operating margins and adjusted EPS, but there are potential risks such as decreased funding and competition in the protein analysis market.
Bears say
Bio-Techne is facing potential risks in the form of a delayed end market recovery, share loss to competitors who have been acquired, and potential disappointment in the progress of cell therapy development. Additionally, there is also a risk associated with the company's acquisition strategy and potential impact from a shift towards software/AI in the biotech industry. While biotech funding has increased in recent months, it has not yet translated into demand for the company's products. Despite this, Bio-Techne remains a global leader in life science tools and has the potential for growth in the future, leading to a price target of $73 from $62.
This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.
Bio-Techne (TECH) Analyst Forecast & Price Prediction
Start investing in Bio-Techne (TECH)
Order type
Buy in
Order amount
Est. shares
0 shares